PRL and hyperprolactinemia: As DAs can be tapered 24 months after initiation of medical therapy when prolactin (PRL) levels are normalized (31), early recurrence of hyperprolactinemia following discontinuation of DAs have been reported, particularly in patients with macroprolactinomas (32–35).